ABVX:EPA
Abivax SA
€76.10
arrow_downward
-0.72%(-0.55) 1D
Nov 19, 5:35:26 PM GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ABVX...
Open
€77.35
High
€79.30
Low
€75.85
Mkt. cap
6.75B
Avg. vol.
110.41K
Volume
0.00
52-wk high
€139.00
52-wk low
€60.45
EPS
-€5.20
Shares outstanding
9.87M
No. of employees
98
Open
€77.35
High
€79.30
Low
€75.85
Mkt. cap
6.75B
Avg. vol.
110.41K
Volume
0.00
52-wk high
€139.00
52-wk low
€60.45
EPS
-€5.20
Shares outstanding
9.87M
No. of employees
98
News stories
From web sources and news partners
The Motley Fool
·
1 hour ago
The S&P 500 Just Fell 4 Straight Weeks From a Record High. Here’s Why I’m Buying the Dip.
FXStreet
·
4 hours ago
Dow Jones Industrial Average falls over 1,000 points as Anthropic IPO dominates
Traders Union
·
3 hours ago
S&P 500 sees $2 trillion swing and 8.5 percent drop, Peter Tuchman notes
BigGo Finance
·
1 hour ago
Chip ETF Eyes Unprecedented Fourth Straight Year of Beating the S&P 500
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
About Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Employees98
FoundedDec 4, 2013
Headquarters-
SectorHealth Care
IndustryPharmaceutical industry
Websiteabivax.com